MovDisordV3, PascalFrancis, Curation, bibRecord, 000167

Botulinum toxin antibody testing : Comparison between the mouse protection assay and the mouse lethality assay

Identifieur interne : 000167 ( PascalFrancis/Curation ); précédent : 000166; suivant : 000168

Botulinum toxin antibody testing : Comparison between the mouse protection assay and the mouse lethality assay

Auteurs : D. Dressier [Royaume-Uni] ; G. Dirnberger [Royaume-Uni] ; K. P. Bhatia [Royaume-Uni] ; A. Irmer [Allemagne] ; N. P. Quinn [Royaume-Uni] ; H. Bigalke [Allemagne] ; C. D. Marsden [Royaume-Uni]

Source :

Movement disorders [ 0885-3185 ] ; 2000.

RBID : Pascal:00-0480420

Descripteurs français

Pascal (Inist)
- Bontoxilysin, Toxine, Botulisme, Anticorps, Dosage, Dystonie, Rachis cervical, Myorésolutif, Spasmolytique, Traitement, Etude comparative, Technique, Exploration immunologique, Homme, Toxicité, Mouse protection assay, Mouse lethality assay.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Antibody, Antispasmodic agent, Assay, Bontoxilysin, Botulism, Cervical spine, Comparative study, Dystonia, Human, Immunological investigation, Muscle relaxant, Technique, Toxicity, Toxin, Treatment.

Abstract

Conventionally, the standard test for detection of antibodies against botulinum toxin (BT-A) has been the mouse lethality assay (MLA). Because this test has a number of disadvantages, a novel mouse protection assay (MPA) was recently introduced. We sought to compare the results of both tests. Forty-three samples from 38 patients with cervical dystonia and complete or partial subjective BT-A therapy failure underwent simultaneous MPA and MLA testing. Twenty-seven samples showed concordant results in both tests. Eleven of them were MPA- and MLA-positive and 16 MPA- and MLA-negative, resulting in a significant association of the dichotomous test results (Fisher exact test, p <0.01). Sixteen samples showed discordant results. All of those were MPA-positive and MLA-negative. This excess of MPA-positive results was also significant (Wilcoxon signed-rank test, p <0.001). Of the patients with MPA-positive samples, 62% had complete and 38% had partial therapy failure. Of the patients with MLA-positive samples, 90% had complete and 10% had partial therapy failure. MPA and MLA results show significant association. Statistical analysis and predominance of partial therapy failure in MPA-positive patients demonstrate higher sensitivity of MPA. With its methodologic advantages, its test parameter being more relevant to BT-A therapy, and its higher sensitivity, the MPA appears to be superior to the MLA.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 15`
A06				`@2 5`
A08	`01`	`1`	`ENG`	`@1 Botulinum toxin antibody testing : Comparison between the mouse protection assay and the mouse lethality assay`
A11	`01`	`1`		`@1 DRESSIER (D.)`
A11	`02`	`1`		`@1 DIRNBERGER (G.)`
A11	`03`	`1`		`@1 BHATIA (K. P.)`
A11	`04`	`1`		`@1 IRMER (A.)`
A11	`05`	`1`		`@1 QUINN (N. P.)`
A11	`06`	`1`		`@1 BIGALKE (H.)`
A11	`07`	`1`		`@1 MARSDEN (C. D.)`
A14	`01`			`@1 Institute of Neurology @2 London @3 GBR @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 5 aut. @Z 7 aut.`
A14	`02`			`@1 Department of Toxicology, Medizinische Hochschule @2 Hannover @3 DEU @Z 4 aut. @Z 6 aut.`
A20				`@1 973-976`
A21				`@1 2000`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000091356830300`
A44				`@0 0000 @1 © 2000 INIST-CNRS. All rights reserved.`
A45				`@0 8 ref.`
A47	`01`	`1`		`@0 00-0480420`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Conventionally, the standard test for detection of antibodies against botulinum toxin (BT-A) has been the mouse lethality assay (MLA). Because this test has a number of disadvantages, a novel mouse protection assay (MPA) was recently introduced. We sought to compare the results of both tests. Forty-three samples from 38 patients with cervical dystonia and complete or partial subjective BT-A therapy failure underwent simultaneous MPA and MLA testing. Twenty-seven samples showed concordant results in both tests. Eleven of them were MPA- and MLA-positive and 16 MPA- and MLA-negative, resulting in a significant association of the dichotomous test results (Fisher exact test, p <0.01). Sixteen samples showed discordant results. All of those were MPA-positive and MLA-negative. This excess of MPA-positive results was also significant (Wilcoxon signed-rank test, p <0.001). Of the patients with MPA-positive samples, 62% had complete and 38% had partial therapy failure. Of the patients with MLA-positive samples, 90% had complete and 10% had partial therapy failure. MPA and MLA results show significant association. Statistical analysis and predominance of partial therapy failure in MPA-positive patients demonstrate higher sensitivity of MPA. With its methodologic advantages, its test parameter being more relevant to BT-A therapy, and its higher sensitivity, the MPA appears to be superior to the MLA.
C02	`01`	`X`		`@0 002B24O14`
C03	`01`	`X`	`FRE`	`@0 Bontoxilysin @2 FE @2 FR @5 01`
C03	`01`	`X`	`ENG`	`@0 Bontoxilysin @2 FE @2 FR @5 01`
C03	`01`	`X`	`SPA`	`@0 Bontoxilysin @2 FE @2 FR @5 01`
C03	`02`	`X`	`FRE`	`@0 Toxine @5 02`
C03	`02`	`X`	`ENG`	`@0 Toxin @5 02`
C03	`02`	`X`	`SPA`	`@0 Toxina @5 02`
C03	`03`	`X`	`FRE`	`@0 Botulisme @5 03`
C03	`03`	`X`	`ENG`	`@0 Botulism @5 03`
C03	`03`	`X`	`SPA`	`@0 Botulismo @5 03`
C03	`04`	`X`	`FRE`	`@0 Anticorps @5 04`
C03	`04`	`X`	`ENG`	`@0 Antibody @5 04`
C03	`04`	`X`	`SPA`	`@0 Anticuerpo @5 04`
C03	`05`	`X`	`FRE`	`@0 Dosage @5 05`
C03	`05`	`X`	`ENG`	`@0 Assay @5 05`
C03	`05`	`X`	`SPA`	`@0 Dosificación @5 05`
C03	`06`	`X`	`FRE`	`@0 Dystonie @5 07`
C03	`06`	`X`	`ENG`	`@0 Dystonia @5 07`
C03	`06`	`X`	`SPA`	`@0 Distonía @5 07`
C03	`07`	`X`	`FRE`	`@0 Rachis cervical @5 08`
C03	`07`	`X`	`ENG`	`@0 Cervical spine @5 08`
C03	`07`	`X`	`SPA`	`@0 Raquis cervical @5 08`
C03	`08`	`X`	`FRE`	`@0 Myorésolutif @5 10`
C03	`08`	`X`	`ENG`	`@0 Muscle relaxant @5 10`
C03	`08`	`X`	`SPA`	`@0 Relajante muscular @5 10`
C03	`09`	`X`	`FRE`	`@0 Spasmolytique @5 11`
C03	`09`	`X`	`ENG`	`@0 Antispasmodic agent @5 11`
C03	`09`	`X`	`SPA`	`@0 Espasmolítico @5 11`
C03	`10`	`X`	`FRE`	`@0 Traitement @5 16`
C03	`10`	`X`	`ENG`	`@0 Treatment @5 16`
C03	`10`	`X`	`SPA`	`@0 Tratamiento @5 16`
C03	`11`	`X`	`FRE`	`@0 Etude comparative @5 17`
C03	`11`	`X`	`ENG`	`@0 Comparative study @5 17`
C03	`11`	`X`	`SPA`	`@0 Estudio comparativo @5 17`
C03	`12`	`X`	`FRE`	`@0 Technique @5 18`
C03	`12`	`X`	`ENG`	`@0 Technique @5 18`
C03	`12`	`X`	`SPA`	`@0 Técnica @5 18`
C03	`13`	`X`	`FRE`	`@0 Exploration immunologique @5 19`
C03	`13`	`X`	`ENG`	`@0 Immunological investigation @5 19`
C03	`13`	`X`	`SPA`	`@0 Análisis inmunológico @5 19`
C03	`14`	`X`	`FRE`	`@0 Homme @5 20`
C03	`14`	`X`	`ENG`	`@0 Human @5 20`
C03	`14`	`X`	`SPA`	`@0 Hombre @5 20`
C03	`15`	`X`	`FRE`	`@0 Toxicité @5 23`
C03	`15`	`X`	`ENG`	`@0 Toxicity @5 23`
C03	`15`	`X`	`SPA`	`@0 Toxicidad @5 23`
C03	`16`	`X`	`FRE`	`@0 Mouse protection assay @4 INC @5 86`
C03	`17`	`X`	`FRE`	`@0 Mouse lethality assay @4 INC @5 87`
C07	`01`	`X`	`FRE`	`@0 Metalloendopeptidases @2 FE`
C07	`01`	`X`	`ENG`	`@0 Metalloendopeptidases @2 FE`
C07	`01`	`X`	`SPA`	`@0 Metalloendopeptidases @2 FE`
C07	`02`	`X`	`FRE`	`@0 Peptidases @2 FE`
C07	`02`	`X`	`ENG`	`@0 Peptidases @2 FE`
C07	`02`	`X`	`SPA`	`@0 Peptidases @2 FE`
C07	`03`	`X`	`FRE`	`@0 Hydrolases @2 FE`
C07	`03`	`X`	`ENG`	`@0 Hydrolases @2 FE`
C07	`03`	`X`	`SPA`	`@0 Hydrolases @2 FE`
C07	`04`	`X`	`FRE`	`@0 Enzyme`
C07	`04`	`X`	`ENG`	`@0 Enzyme`
C07	`04`	`X`	`SPA`	`@0 Enzima`
C07	`05`	`X`	`FRE`	`@0 Bactériose`
C07	`05`	`X`	`ENG`	`@0 Bacteriosis`
C07	`05`	`X`	`SPA`	`@0 Bacteriosis`
C07	`06`	`X`	`FRE`	`@0 Infection`
C07	`06`	`X`	`ENG`	`@0 Infection`
C07	`06`	`X`	`SPA`	`@0 Infección`
C07	`07`	`X`	`FRE`	`@0 Muscle strié pathologie @5 53`
C07	`07`	`X`	`ENG`	`@0 Striated muscle disease @5 53`
C07	`07`	`X`	`SPA`	`@0 Músculo estriado patología @5 53`
C07	`08`	`X`	`FRE`	`@0 Système nerveux pathologie @5 54`
C07	`08`	`X`	`ENG`	`@0 Nervous system diseases @5 54`
C07	`08`	`X`	`SPA`	`@0 Sistema nervioso patología @5 54`
C07	`09`	`X`	`FRE`	`@0 Trouble neurologique @5 55`
C07	`09`	`X`	`ENG`	`@0 Neurological disorder @5 55`
C07	`09`	`X`	`SPA`	`@0 Trastorno neurológico @5 55`
C07	`10`	`X`	`FRE`	`@0 Mouvement involontaire @5 56`
C07	`10`	`X`	`ENG`	`@0 Involuntary movement @5 56`
C07	`10`	`X`	`SPA`	`@0 Movimiento involuntario @5 56`
C07	`11`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 57`
C07	`11`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 57`
C07	`11`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 57`
N21				`@1 318`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002B54

Links to Exploration step

Pascal:00-0480420

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Botulinum toxin antibody testing : Comparison between the mouse protection assay and the mouse lethality assay</title>
<author><name sortKey="Dressier, D" sort="Dressier, D" uniqKey="Dressier D" first="D." last="Dressier">D. Dressier</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Institute of Neurology</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Dirnberger, G" sort="Dirnberger, G" uniqKey="Dirnberger G" first="G." last="Dirnberger">G. Dirnberger</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Institute of Neurology</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Bhatia, K P" sort="Bhatia, K P" uniqKey="Bhatia K" first="K. P." last="Bhatia">K. P. Bhatia</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Institute of Neurology</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Irmer, A" sort="Irmer, A" uniqKey="Irmer A" first="A." last="Irmer">A. Irmer</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Toxicology, Medizinische Hochschule</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Quinn, N P" sort="Quinn, N P" uniqKey="Quinn N" first="N. P." last="Quinn">N. P. Quinn</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Institute of Neurology</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Bigalke, H" sort="Bigalke, H" uniqKey="Bigalke H" first="H." last="Bigalke">H. Bigalke</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Toxicology, Medizinische Hochschule</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Institute of Neurology</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">00-0480420</idno>
<date when="2000">2000</date>
<idno type="stanalyst">PASCAL 00-0480420 INIST</idno>
<idno type="RBID">Pascal:00-0480420</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002B54</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000167</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Botulinum toxin antibody testing : Comparison between the mouse protection assay and the mouse lethality assay</title>
<author><name sortKey="Dressier, D" sort="Dressier, D" uniqKey="Dressier D" first="D." last="Dressier">D. Dressier</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Institute of Neurology</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Dirnberger, G" sort="Dirnberger, G" uniqKey="Dirnberger G" first="G." last="Dirnberger">G. Dirnberger</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Institute of Neurology</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Bhatia, K P" sort="Bhatia, K P" uniqKey="Bhatia K" first="K. P." last="Bhatia">K. P. Bhatia</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Institute of Neurology</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Irmer, A" sort="Irmer, A" uniqKey="Irmer A" first="A." last="Irmer">A. Irmer</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Toxicology, Medizinische Hochschule</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Quinn, N P" sort="Quinn, N P" uniqKey="Quinn N" first="N. P." last="Quinn">N. P. Quinn</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Institute of Neurology</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Bigalke, H" sort="Bigalke, H" uniqKey="Bigalke H" first="H." last="Bigalke">H. Bigalke</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Toxicology, Medizinische Hochschule</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Institute of Neurology</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2000">2000</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibody</term>
<term>Antispasmodic agent</term>
<term>Assay</term>
<term>Bontoxilysin</term>
<term>Botulism</term>
<term>Cervical spine</term>
<term>Comparative study</term>
<term>Dystonia</term>
<term>Human</term>
<term>Immunological investigation</term>
<term>Muscle relaxant</term>
<term>Technique</term>
<term>Toxicity</term>
<term>Toxin</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Bontoxilysin</term>
<term>Toxine</term>
<term>Botulisme</term>
<term>Anticorps</term>
<term>Dosage</term>
<term>Dystonie</term>
<term>Rachis cervical</term>
<term>Myorésolutif</term>
<term>Spasmolytique</term>
<term>Traitement</term>
<term>Etude comparative</term>
<term>Technique</term>
<term>Exploration immunologique</term>
<term>Homme</term>
<term>Toxicité</term>
<term>Mouse protection assay</term>
<term>Mouse lethality assay</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Conventionally, the standard test for detection of antibodies against botulinum toxin (BT-A) has been the mouse lethality assay (MLA). Because this test has a number of disadvantages, a novel mouse protection assay (MPA) was recently introduced. We sought to compare the results of both tests. Forty-three samples from 38 patients with cervical dystonia and complete or partial subjective BT-A therapy failure underwent simultaneous MPA and MLA testing. Twenty-seven samples showed concordant results in both tests. Eleven of them were MPA- and MLA-positive and 16 MPA- and MLA-negative, resulting in a significant association of the dichotomous test results (Fisher exact test, p <0.01). Sixteen samples showed discordant results. All of those were MPA-positive and MLA-negative. This excess of MPA-positive results was also significant (Wilcoxon signed-rank test, p <0.001). Of the patients with MPA-positive samples, 62% had complete and 38% had partial therapy failure. Of the patients with MLA-positive samples, 90% had complete and 10% had partial therapy failure. MPA and MLA results show significant association. Statistical analysis and predominance of partial therapy failure in MPA-positive patients demonstrate higher sensitivity of MPA. With its methodologic advantages, its test parameter being more relevant to BT-A therapy, and its higher sensitivity, the MPA appears to be superior to the MLA.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>15</s2>
</fA05>
<fA06><s2>5</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Botulinum toxin antibody testing : Comparison between the mouse protection assay and the mouse lethality assay</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>DRESSIER (D.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>DIRNBERGER (G.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>BHATIA (K. P.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>IRMER (A.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>QUINN (N. P.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>BIGALKE (H.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>MARSDEN (C. D.)</s1>
</fA11>
<fA14 i1="01"><s1>Institute of Neurology</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Toxicology, Medizinische Hochschule</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA20><s1>973-976</s1>
</fA20>
<fA21><s1>2000</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000091356830300</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2000 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>8 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>00-0480420</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Conventionally, the standard test for detection of antibodies against botulinum toxin (BT-A) has been the mouse lethality assay (MLA). Because this test has a number of disadvantages, a novel mouse protection assay (MPA) was recently introduced. We sought to compare the results of both tests. Forty-three samples from 38 patients with cervical dystonia and complete or partial subjective BT-A therapy failure underwent simultaneous MPA and MLA testing. Twenty-seven samples showed concordant results in both tests. Eleven of them were MPA- and MLA-positive and 16 MPA- and MLA-negative, resulting in a significant association of the dichotomous test results (Fisher exact test, p <0.01). Sixteen samples showed discordant results. All of those were MPA-positive and MLA-negative. This excess of MPA-positive results was also significant (Wilcoxon signed-rank test, p <0.001). Of the patients with MPA-positive samples, 62% had complete and 38% had partial therapy failure. Of the patients with MLA-positive samples, 90% had complete and 10% had partial therapy failure. MPA and MLA results show significant association. Statistical analysis and predominance of partial therapy failure in MPA-positive patients demonstrate higher sensitivity of MPA. With its methodologic advantages, its test parameter being more relevant to BT-A therapy, and its higher sensitivity, the MPA appears to be superior to the MLA.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B24O14</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Bontoxilysin</s0>
<s2>FE</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Bontoxilysin</s0>
<s2>FE</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Bontoxilysin</s0>
<s2>FE</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Toxine</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Toxin</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Toxina</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Botulisme</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Botulism</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Botulismo</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Anticorps</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Antibody</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Anticuerpo</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Dosage</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Assay</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Dosificación</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Dystonie</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Dystonia</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Distonía</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Rachis cervical</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Cervical spine</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Raquis cervical</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Myorésolutif</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Muscle relaxant</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Relajante muscular</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Spasmolytique</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Antispasmodic agent</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Espasmolítico</s0>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Traitement</s0>
<s5>16</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Treatment</s0>
<s5>16</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>16</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Etude comparative</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Comparative study</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Estudio comparativo</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Technique</s0>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Technique</s0>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Técnica</s0>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Exploration immunologique</s0>
<s5>19</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Immunological investigation</s0>
<s5>19</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Análisis inmunológico</s0>
<s5>19</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Toxicité</s0>
<s5>23</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Toxicity</s0>
<s5>23</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Toxicidad</s0>
<s5>23</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Mouse protection assay</s0>
<s4>INC</s4>
<s5>86</s5>
</fC03>
<fC03 i1="17" i2="X" l="FRE"><s0>Mouse lethality assay</s0>
<s4>INC</s4>
<s5>87</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Metalloendopeptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Metalloendopeptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Metalloendopeptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Peptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Peptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Peptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Enzyme</s0>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Enzyme</s0>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Enzima</s0>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Bactériose</s0>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Bacteriosis</s0>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Bacteriosis</s0>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Muscle strié pathologie</s0>
<s5>53</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Striated muscle disease</s0>
<s5>53</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Músculo estriado patología</s0>
<s5>53</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>54</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>54</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>54</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>55</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>55</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>55</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Mouvement involontaire</s0>
<s5>56</s5>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Involuntary movement</s0>
<s5>56</s5>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Movimiento involuntario</s0>
<s5>56</s5>
</fC07>
<fC07 i1="11" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>57</s5>
</fC07>
<fC07 i1="11" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>57</s5>
</fC07>
<fC07 i1="11" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>57</s5>
</fC07>
<fN21><s1>318</s1>
</fN21>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000167 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000167 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:00-0480420
   |texte=   Botulinum toxin antibody testing : Comparison between the mouse protection assay and the mouse lethality assay
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Botulinum toxin antibody testing : Comparison between the mouse protection assay and the mouse lethality assay

Botulinum toxin antibody testing : Comparison between the mouse protection assay and the mouse lethality assay

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri